kaken pharm - KKPCF

KKPCF

Close Chg Chg %
28.12 -2.12 -7.54%

Closed Market

26.00

-2.12 (7.54%)

Volume: 200.00

Last Updated:

Jan 13, 2026, 1:05 PM EDT

Company Overview: kaken pharm - KKPCF

KKPCF Key Data

Open

$26.00

Day Range

26.00 - 26.00

52 Week Range

23.65 - 28.12

Market Cap

$1.02B

Shares Outstanding

37.87M

Public Float

22.31M

Beta

0.28

Rev. Per Employee

N/A

P/E Ratio

203.75

EPS

$0.13

Yield

422.57%

Dividend

$0.60

EX-DIVIDEND DATE

Mar 30, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

KKPCF Performance

No Data Available

KKPCF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About kaken pharm - KKPCF

Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operates through the Pharmaceutical and Real Estate business segments. The Pharmaceutical segment mainly manufactures and sells pharmaceuticals, medical devices and agricultural chemicals. The Real Estate segment rents real estate related to Bunkyo Green Court. The company was founded in March 1917 and is headquartered in Tokyo, Japan.

KKPCF At a Glance

Kaken Pharmaceutical Co., Ltd.
2-28-8 Honkomagome
Tokyo, Tokyo 113-8650
Phone 81-3-5977-5001 Revenue 616.82M
Industry Pharmaceuticals: Major Net Income 91.47M
Sector Health Technology 2025 Sales Growth 23.643%
Fiscal Year-end 03 / 2026 Employees 1,126
View SEC Filings

KKPCF Valuation

P/E Current 203.75
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.502
Price to Sales Ratio 1.854
Price to Book Ratio 1.127
Price to Cash Flow Ratio 5.85
Enterprise Value to EBITDA 4.528
Enterprise Value to Sales 1.136
Total Debt to Enterprise Value 0.037

KKPCF Efficiency

Revenue/Employee 547,800.803
Income Per Employee 81,236.584
Receivables Turnover 4.355
Total Asset Turnover 0.512

KKPCF Liquidity

Current Ratio 3.669
Quick Ratio 3.043
Cash Ratio 2.309

KKPCF Profitability

Gross Margin 61.958
Operating Margin 22.37
Pretax Margin 20.668
Net Margin 14.83
Return on Assets 7.599
Return on Equity 9.284
Return on Total Capital 8.741
Return on Invested Capital 9.284

KKPCF Capital Structure

Total Debt to Total Equity 2.522
Total Debt to Total Capital 2.46
Total Debt to Total Assets 2.022
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kaken Pharm - KKPCF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
676.67M 538.77M 498.87M 616.82M
Sales Growth
-4.28% -20.38% -7.41% +23.64%
Cost of Goods Sold (COGS) incl D&A
308.96M 248.92M 234.20M 234.65M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
22.08M 18.96M 19.06M 16.75M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
-4.46% -19.43% -5.91% +0.19%
Gross Income
367.71M 289.86M 264.67M 382.17M
Gross Income Growth
-4.12% -21.17% -8.69% +44.39%
Gross Profit Margin
+54.34% +53.80% +53.05% +61.96%
2022 2023 2024 2025 5-year trend
SG&A Expense
215.84M 230.80M 198.79M 244.18M
Research & Development
74.93M 116.56M 86.85M 122.83M
Other SG&A
140.91M 114.25M 111.94M 121.36M
SGA Growth
+0.01% +6.93% -13.87% +22.84%
Other Operating Expense
- - - -
-
Unusual Expense
33.49M 13.75M 131.57K 13.28M
EBIT after Unusual Expense
118.38M 45.30M 65.75M 124.70M
Non Operating Income/Expense
5.35M 5.16M 2.22M 2.98M
Non-Operating Interest Income
53.40K 51.67K 55.40K 505.08K
Equity in Earnings of Affiliates
- (199.32K) (145.42K) (216.46K)
Interest Expense
151.29K 125.50K 117.72K 183.67K
Interest Expense Growth
-5.61% -17.05% -6.20% +56.02%
Gross Interest Expense
151.29K 125.50K 117.72K 183.67K
Interest Capitalized
- - - -
-
Pretax Income
123.57M 50.32M 67.83M 127.48M
Pretax Income Growth
-29.75% -59.28% +34.79% +87.94%
Pretax Margin
+18.26% +9.34% +13.60% +20.67%
Income Tax
38.59M 10.17M 12.26M 36.01M
Income Tax - Current - Domestic
40.16M 29.51M 13.34M 50.63M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.58M) (19.35M) (1.07M) (14.61M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (199.32K) (145.42K) (216.46K)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
84.98M 40.16M 55.57M 91.47M
Minority Interest Expense
- - - -
-
Net Income
84.98M 40.16M 55.57M 91.47M
Net Income Growth
-32.76% -52.74% +38.38% +64.61%
Net Margin Growth
+12.56% +7.45% +11.14% +14.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
84.98M 40.16M 55.57M 91.47M
Preferred Dividends
- - - -
-
Net Income Available to Common
84.98M 40.16M 55.57M 91.47M
EPS (Basic)
2.2377 1.0689 1.4726 2.3969
EPS (Basic) Growth
-31.68% -52.23% +37.77% +62.77%
Basic Shares Outstanding
37.98M 37.57M 37.74M 38.16M
EPS (Diluted)
2.2377 1.0689 1.4726 2.3969
EPS (Diluted) Growth
-31.68% -52.23% +37.77% +62.77%
Diluted Shares Outstanding
37.98M 37.57M 37.74M 38.16M
EBITDA
173.95M 78.01M 84.94M 154.74M
EBITDA Growth
-8.24% -55.15% +8.88% +82.17%
EBITDA Margin
+25.71% +14.48% +17.03% +25.09%

Kaken Pharm in the News